| Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. | |
| | |
MedLine Citation:
|
PMID: 21544313 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Edoxaban, an oral direct factor Xa (FXa) inhibitor, is in phase III clinical development for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. The shed blood model allows for study of activated coagulation at a site of standardised tissue injury due to local release of tissue factor. The objective of this study was to evaluate the effect of three doses of edoxaban on markers of coagulation in shed and venous blood versus placebo and a standard prophylactic dose of fondaparinux. A total of 100 healthy male subjects were randomised to receive single doses of one of five treatments: subcutaneously administered fondaparinux 2.5 mg; orally administered edoxaban 30, 60, or 120 mg; or placebo. The primary objective was measurement of blood coagulation markers prothrombin fragment 1+2 (F1+2) and thrombin-antithrombin (TAT) complex, and platelet activation marker β-thromboglobulin (β-TG), in venous and shed blood. Secondary objectives included pharmacokinetics, shed blood volume, and safety of edoxaban. Single doses of edoxaban caused rapid and significant decreases of F1+2, TAT, and β-TG in the shed blood model, indicating inhibition of thrombin generation and platelet activation. Inhibition was significantly less for fondaparinux versus edoxaban. Baseline-corrected F1+2, TAT, and β-TG values demonstrated sustained inhibition up to 24 hours for shed blood in the edoxaban groups but no significant inhibition in venous blood. Overall, edoxaban treatments were well tolerated. In conclusion, single oral doses of edoxaban 30, 60, or 120 mg caused rapid and sustained inhibition of coagulation up to 24 hours in the shed blood model. |
| | |
Authors:
|
M Wolzt; M M Samama; S Kapiotis; K Ogata; J Mendell; S Kunitada |
Related Documents
:
|
15934993 - Why don't young people volunteer to give blood? an investigation of the correlates of d... 19864773 - Importance of confirmatory testing in donated blood. 533953 - Effects of distension on mesenteric blood flow and o2 saturation of venous blood in the... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2011-05-05 |
Journal Detail:
|
Title: Thrombosis and haemostasis Volume: 105 ISSN: 0340-6245 ISO Abbreviation: Thromb. Haemost. Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-06-07 Completed Date: 2011-10-27 Revised Date: 2012-01-10 |
Medline Journal Info:
|
Nlm Unique ID: 7608063 Medline TA: Thromb Haemost Country: Germany |
Other Details:
|
Languages: eng Pagination: 1080-90 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacology, Medical University of Vienna, Allgemeines Krankenhaus Wien, A-1090 Vienna, Austria. michael.wolzt@meduniwien.ac.at |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antithrombin III Biological Markers / blood Blood Coagulation* / drug effects Clinical Protocols Clinical Trials, Phase III as Topic Drug Dosage Calculations* Factor Xa / antagonists & inhibitors Humans Male Peptide Fragments / blood Peptide Hydrolases / blood Platelet Activation / drug effects Polysaccharides / administration & dosage, adverse effects Prothrombin Pyridines / administration & dosage*, adverse effects, pharmacokinetics, pharmacology Thiazoles / administration & dosage*, adverse effects, pharmacokinetics, pharmacology beta-Thromboglobulin / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Peptide Fragments; 0/Polysaccharides; 0/Pyridines; 0/Thiazoles; 0/antithrombin III-protease complex; 0/beta-Thromboglobulin; 0/fondaparinux; 0/prothrombin fragment 1.2; 480449-70-5/edoxaban; 9000-94-6/Antithrombin III; 9001-26-7/Prothrombin; EC 3.4.-/Peptide Hydrolases; EC 3.4.21.6/Factor Xa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they real...
Next Document: Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy.